An Estimation of the Population Survival Benefit of First-Line Chemotherapy for Upper Gastrointestinal Cancer. (#1)

12:45 PM

Viet Do

Competitive Allele Sequence Taqman (CastPCR) technique for sensitive detection of KRAS and BRAF mutations in colorectal cancer. (#2)

12:45 PM

Kerryn Garrett

Do patients achieving pathological complete response (pCR) following neoadjuvant treatment for locally advanced rectal cancer (LARC) need adjuvant chemotherapy? (#3)

12:45 PM

Anis Hamid

Delivering adjuvant chemotherapy for colon cancer according to standard protocols in routine clinical practice: Feasibility and outcomes from two metropolitan hospitals (#4)

12:45 PM

Christopher D Hart

Reporting PTEN status in advanced colorectal cancer, time for standardisation? (#5)

12:45 PM

Christopher Hocking

Indigenous patients and metastatic colorectal cancer: Results from the South Australian  (SA) metastatic colorectal cancer (mCRC) registry (#6)

12:45 PM

Christopher Hocking

A randomised, placebo-controlled, double-blind phase 2 trial of peri-operative cimetidine in early colorectal cancer (#7)

12:45 PM

Michael B Jameson

Single institution experience: Factors influencing timing of adjuvant chemotherapy in early stage colorectal cancer. (#8)

12:45 PM

Bhaskar Karki

Prognostic value of systemic inflammation-based neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and modified Glasgow Prognostic Score in advanced pancreatic cancer (#9)

12:45 PM

Muhammad A Khattak

NATURAL KILLER CELLS IN RECTAL CANCERS TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY   (#10)

12:45 PM

Stephanie H Lim

Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC) (#11)

12:45 PM

Kiley Loh

Do regulatory T cells inhibit the response of rectal carcinomas to neoadjuvant chemoradiotherapy? (#12)

12:45 PM

Melanie J McCoy

Serial CEA measurements for patients on adjuvant chemotherapy for colon cancer; patterns and relationship with overall survival. (#13)

12:45 PM

Nicola Mitchell

The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90). The South Australian (SA) experience. (#14)

12:45 PM

Sunita Padman

Patterns of care of elderly patients with metastatic colorectal cancer (#15)

12:45 PM

Desmond Yip

Predictors of outcome after surgery for gastric cancer in a Western cohort (#16)

12:45 PM

Sharon Pattison

First-line cetuximab with FOLFOX or FOLFIRI every 2 weeks in KRAS wild-type metastatic colorectal cancer: phase II APEC study (#17)

12:45 PM

Timothy Price

Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the TRACC database. (#18)

12:45 PM

Aflah Roohullah

Analysis of KRAS/NRAS mutations in PEAK: A randomised phase II study of FOLFOX6 plus panitumumab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) (#19)

12:45 PM

Lee Schwartzberg

Meta-analysis of overall survival impact of biological therapy in relapsed metastatic colorectal cancer (#20)

12:45 PM

Eva Segelov

Circulating tumour DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (#21)

12:45 PM

Jeanne Tie

A PHASE IB STUDY OF SECOND-LINE THERAPY WITH PANITUMUMAB, IRINOTECAN AND EVEROLIMUS (PIE) IN METASTATIC COLORECTAL CANCER (mCRC) WITH KRAS WILD TYPE (WT) (#22)

12:45 PM

Amanda Townsend

Making personalized medicine a reality: practical lessons from a next generation sequencing-driven clinical trial in pancreatic cancer (#23)

12:45 PM

Clare Watson

Resection of colorectal cancer (CRC) metastases in routine practice (#24)

12:45 PM

Hui-li Wong

Predictive biomarkers to mTORC1 inhibitors in biliary tract cancer (#25)

12:45 PM

Yvonne Yeung